This proposal will explore the rational synthesis and pharmacological evaluation of novel drug candidates for the treatment of Parkinson s disease (PD). The proposal will focus on the investigation of heterobivalent ligands that are designed to simultaneously target two G protein-coupled receptors, namely central dopamine D2 and adenosine A2A, to alleviate the symptoms of this devastating neurodegenerative disease. The expected outcomes will be the significant advancement and progression of research in the area of PD and quality scientific publications in high impact-factor journals which will greatly enhance our international standing.
|Effective start/end date||1/07/10 → 31/12/13|
- Australian Research Council (ARC): AUD78,420.00
- GlaxoSmithKline (GSK) Singapore: AUD18,000.00